Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
CUPR
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.66 – $1.71
Volume2,492
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for CUPR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for CUPR.
Recent news
Company coverage with links to the original publishers.
Cuprina Holdings (Nasdaq: CUPR), a biomedical company, announced the successful closing of its underwriter's over-allotment option, selling an additional 648,373 Class A ordinary shares at $1.15 per share for approximately $745,629 in gross proceeds. Combined with the initial public offering, the company raised total aggregate gross proceeds of approximately $5.72 million, which will be used for business expansion, R&D activities, market growth, and general corporate purposes.
Cuprina Holdings (Nasdaq: CUPR), a biomedical company focused on chronic wounds, infertility, medical waste recycling, and cosmeceuticals, closed its public offering of 4.32 million Class A Ordinary Shares at $1.15 per share, raising approximately $4.97 million in gross proceeds. The company plans to use net proceeds for R&D expansion, new market entry, brand building, and infrastructure investment. The offering follows FDA 510(k) clearance for MEDIFLY Maggots™ in June.
Cuprina Holdings (NASDAQ: CUPR) surged 111.84% intraday to $8.41 after receiving FDA 510(k) clearance for MEDIFLY Maggots, a maggot debridement product for non-healing wounds. The stock subsequently fell 22.47% to $6.52 in after-hours trading. MEDIFLY Maggots is the first maggot debridement product using Lucilia cuprina species to receive FDA clearance, giving the Singapore-based biomedical company commercial rights to both maggot species used in the therapy.
Cuprina Holdings (NASDAQ: CUPR) stock experienced muted trading on Monday after surging 64.73% on Friday following the company's announcement that it regained compliance with Nasdaq Capital Market listing requirements. The Singapore-based biomedical company had previously faced delisting risk due to failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. With the immediate catalyst priced in, traders adopted a wait-and-see approach, with shares down 1.76% in premarket trading.
Cuprina Holdings completed a 1-for-8 reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination. The company failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share despite having until May 26, 2026 to do so. The hearing request will stay the suspension of trading pending the Panel's decision, and the company expects the share consolidation to bring its bid price into compliance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.